Rhythm Pharmaceuticals (RYTM) Accounts Payables (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Accounts Payables data on file, last reported at $12.3 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $12.3 million, up 3.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (up 3.25% YoY), and the FY2025 annual result was $13.9 million, up 13.13% from the prior year.
• Accounts Payables eased to $12.3 million in Q1 2026 per RYTM's latest filing, from $13.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $16.0 million in Q2 2025 and troughed at $3.8 million in Q3 2023.
• A 5-year average of $9.1 million and a median of $8.4 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 45.81% in 2024, then surged 251.79% in 2025.
• A 5-year view of Accounts Payables shows it stood at $4.8 million in 2022, then rose by 1.83% to $4.9 million in 2023, then jumped by 152.36% to $12.3 million in 2024, then gained by 13.13% to $13.9 million in 2025, then retreated by 11.82% to $12.3 million in 2026.
• Business Quant data shows RYTM's Accounts Payables at $12.3 million in Q1 2026, $13.9 million in Q4 2025, and $13.6 million in Q3 2025.